• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 461654 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414161079 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414161079 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Buyers Accumulate Shares of United Therapeutics, Up 1.6%

Published on Mon, 03/18/2013 - 12:29
By Mallory Stone

United Therapeutics (NASDAQ:UTHR), a company whose shares are moving quickly, is trading 1.6% higher to $62.01. The Dow is trading fractionally lower to 14,492 and the S&P is currently down 0.3% to 1,555.

In the past 52 weeks, United Therapeutics share prices have been bracketed by a low of $36.55 and a high of $70.74 and are now at $62.01, 70% above that low price. The 200-day and 50-day moving averages have moved 0.90% higher and 1.65% higher over the past week, respectively.

United Therapeutics (NASDAQ:UTHR) is currently priced 8.5% above its average consensus analyst price target of $56.73. The stock should discover initial support at its 50-day moving average (MA) of $55.84 and subsequent support at its 200-day MA of $53.10.

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.

By Mallory Stone
mstone@fnno.com

Latest News from FNNO

Computer Sciences (CSC) Approaches New U...

Shares of Computer Sciences (NYSE:CSC) opened today above their pivot of $59.16 and hav ...

Watch for Shares of Compuware (CPWR) to ...

Shares of Compuware (NASDAQ:CPWR) have bullishly opened above the pivot of $9.97 today ...

Range Resources (RRC) Breaks Through Sup...

Shares of Range Resources (NYSE:RRC) opened today below their pivot of $68.66 and have ...

Nicor (GAS) Breaks Through Support at $5...

Nicor (NYSE:GAS) has opened bearishly below the pivot of $54.41 today and has reached t ...

Eastman Chemical (EMN) Crosses Pivot Poi...

Shares of Eastman Chemical (NYSE:EMN) opened today below their pivot of $78.05 and have ...

Next Resistance Level for PG&E (PCG) is ...

PG&E (NYSE:PCG) has opened bullishly above the pivot of $46.28 today and has reached th ...

Coca-Cola Enterprises (CCE) Breaks Throu...

Shares of Coca-Cola Enterprises (NYSE:CCE) have bearishly opened below the pivot of $42 ...

Watch for Shares of Ventas (VTR) to Appr...

Shares of Ventas (NYSE:VTR) opened today below their pivot of $67.63 and have already r ...